

Title (en)  
USING TARGETED RADIOTHERAPY (TRT) TO DRIVE ANTI-TUMOR IMMUNE RESPONSE TO IMMUNOTHERAPIES

Title (de)  
VERWENDUNG EINER GEZIELTEN STRAHLENTHERAPIE (TRT) ZUR AUSLÖSUNG EINER ANTITUMOR-IMMUNANTWORT BEI IMMUNOTHERAPIEN

Title (fr)  
UTILISATION D'UNE RADIOTHÉRAPIE CIBLÉE (TRT) EN VUE DE DÉCLENCHER UNE RÉPONSE IMMUNITAIRE ANTITUMORALE À DES IMMUNOTHÉRAPIES

Publication  
**EP 3706808 A1 20200916 (EN)**

Application  
**EP 18819480 A 20181109**

Priority  
• US 201715809427 A 20171110  
• US 2018059927 W 20181109

Abstract (en)  
[origin: WO2019094657A1] The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is -N+(CH3)3.

IPC 8 full level  
**A61K 51/04** (2006.01); **A61K 39/395** (2006.01); **A61N 5/10** (2006.01); **A61P 35/00** (2006.01); **A61P 35/04** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EP IL KR)  
**A61K 9/0019** (2013.01 - IL KR); **A61K 45/06** (2013.01 - KR); **A61K 51/0408** (2013.01 - EP IL KR); **A61K 51/0482** (2013.01 - KR); **A61K 51/0497** (2013.01 - EP IL KR); **A61N 5/1001** (2013.01 - IL); **A61P 35/00** (2017.12 - KR); **C07K 16/3084** (2013.01 - EP IL KR); **A61K 9/0019** (2013.01 - EP); **A61N 5/1001** (2013.01 - EP KR); **A61N 2005/1021** (2013.01 - EP IL KR); **A61N 2005/1098** (2013.01 - EP IL KR); **C07K 2317/24** (2013.01 - EP IL KR); **C07K 2319/74** (2013.01 - EP IL KR)

Citation (search report)  
See references of WO 2019094657A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

DOCDB simple family (publication)  
**WO 2019094657 A1 20190516**; AU 2018366219 A1 20200611; CA 3082056 A1 20190516; CN 111565762 A 20200821; EP 3706808 A1 20200916; IL 274518 A 20200630; JP 2021502368 A 20210128; JP 2023179556 A 20231219; KR 20200088374 A 20200722

DOCDB simple family (application)  
**US 2018059927 W 20181109**; AU 2018366219 A 20181109; CA 3082056 A 20181109; CN 201880086000 A 20181109; EP 18819480 A 20181109; IL 27451820 A 20200507; JP 2020525860 A 20181109; JP 2023160419 A 20230925; KR 20207016410 A 20181109